Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALTO-300 in Major Depressive Disorder
NCT05922878Phase 2Recruiting
- Sponsor
- Alto Neuroscience
- Start
- Jun 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of agomelatine in major depressive disorder (MDD), sponsored by Alto Neuroscience. Started Jun 2023; status: recruiting.
02
Drugs
agomelatine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05922878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05922878.